A Clinical Study of the Safety and Efficacy of a Wearable Device (CLS UF) That Delivers Continuous Administration of Glucose to Recirculated Peritoneal Dialysis Fluid for the Purpose of Ultrafiltration in Patients With Congestive Heart Failure

Inclusion Criteria: * Male or female patient, 18-80 years of age. * Prevalent PD patients with CHF with cardio-renal syndrome type II, on stable ultrafiltration, for more than two months, treated with PD based UF according to German national guidelines. * Therapy resistance of pharmacologic therapy: resistant hypervolemia with ascites, pleural fluid and pulmonary edema * Recurrent hospitalization with cardiac decompensation, ≥ 2 occasions during the last six months * Isolated failure of the right heart chamber * Treatment based on night time APD therapy combined with a day time long dwell. * Obtained written consent to participate in the study. Exclusion Criteria: * End stage renal disease requiring dialysis. * Malignant disease. * On-going infection. * Diabetes mellitus. * HIV and/or hepatitis positive. * Pregnancy. * Breastfeeding women. * Participation in other clinical trials within one month before inclusion. * Abdominal hernia. * Cardiac diseases other than left ventricular heart failure, biventricular heart failure or isolated right heart chamber failure, with volume overload. * Any immune deficiency.